Alligator Bioscience AB (publ) (0RK9.L)

1,1200 -0,1220 (-9,82%) Alla chiusura: 09:35AM BST

Alligator Bioscience AB (publ)

Medicon Village
Scheelevägen 2
Lund 223 81
Sweden
46 4 65 40 82 00
https://www.alligatorbioscience.se

Settore/i: 
Settore: 
Impiegati a tempo pieno: 58

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Søren Bregenholt Ph.D.	Chief Executive Officer	5,2M	N/D	1971
Ms. Marie Svensson	Chief Financial Officer	N/D	N/D	1964
Ms. Laura von Schantz	Chief Technology Officer	N/D	N/D	1982
Dr. Peter Ellmark Ph.D.	Chief Scientific Officer	N/D	N/D	1973
Ms. Julie Silber	Director of Communications & Investor Relations	N/D	N/D	N/D
Dr. Sumeet Ambarkhane M.D.	Chief Medical Officer	N/D	N/D	1968

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in SEK.

Descrizione

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. The company's product portfolio includes Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage. It also offers ALG.APV-527, a bispecific antibody that targets the 4-1BB and 5T4 molecules, which is in phase 1 clinical trial for the treatment of solid metastatic tumors; and ATOR-1017, an immunostimulatory antibody, which is in phase 1 clinical trial for the treatment of metastatic cancer. In addition, the company develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; ALLIGATOR-FAB, which is built on multiple scaffolds with optimal drug development properties to further increase the structural diversity of generated antibodies; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. Further, it has collaboration and out-licensing agreements with Aptevo Therapeutics, Inc.; Orion Corporation.; MacroGenics, Inc.; Biotheus Inc.; BioArctic AB; and Abclon Inc. The company was founded in 2000 and is headquartered in Lund, Sweden.

Governance aziendale

L'ISS Governance QualityScore di Alligator Bioscience AB (publ) al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.